Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 6/2021

31.10.2021 | The Science of Prevention (R Heffron and K Ngure, Section Editors)

Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research

verfasst von: Elizabeth Irungu, Nomhle Khoza, Jennifer Velloza

Erschienen in: Current HIV/AIDS Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This review summarizes interventions to promote HIV pre-exposure prophylaxis (PrEP) use among adolescent girls and young women (AGYW) in HIV endemic settings, while also highlighting gaps in our current measures of PrEP intervention success.

Recent findings

AGYW report challenges with PrEP use, although the field is currently grappling with defining metrics of optimal PrEP use applicable for AGYW with dynamic HIV prevention needs. Ongoing studies are exploring multilevel interventions to address barriers to PrEP use for AGYW. At the individual and interpersonal levels, mHealth, drug-level feedback, adherence counseling, peer groups, and PrEP decision-support interventions are acceptable and feasible for AGYW although limited effectiveness data are available. At the health facility and community levels, PrEP demand creation, modified PrEP refill schedules, and integrated PrEP and reproductive health services are also promising options to support PrEP use for AGYW.

Summary

As PrEP delivery continues to expand, improved metrics of success and evidence on the effectiveness of multi-level adherence support interventions are needed to maximize the impact of PrEP for AGYW in HIV endemic settings. We present case studies of these intervention approaches but limited data are currently available on the effectiveness of these approaches. We will look toward forthcoming study results on the impact of PrEP interventions, including mHealth, drug-level feedback and other enhanced counseling, peer support, decision-support tools, PrEP demand creation, modified refills, and integrated service delivery, to determine the ideal package of PrEP support approaches for AGYW.
Literatur
1.
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.CrossRef
2.
• Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019 27;394(10195):303–13. This article provides data from the first randomized controlled assessing the effect of hormonal and non-hormonal contraceptive options on HIV risk. The authors did not find a substantial difference in HIV risk by contraceptive method, indicating the importance of contraceptive method choice for young women in HIV endemic settings.
3.
UNAIDS. Trend in new infections: Eastern, Southern, Western, Central Africa by Sex. [Internet]. 2018 [cited 2019 Jul 31]. Available from: aidsinfo.unaids.org
4.
Baggaley R, Armstrong A, Dodd Z, Ngoksin E, Krug A. Young key populations and HIV: a special emphasis and consideration in the new WHO Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. J Int AIDS Soc. 2015;18(2 Suppl 1):19438.CrossRef
5.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRef
6.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRef
7.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRef
8.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRef
9.
Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2017;5(2):e68–78.CrossRef
10.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017 01;74(1):21–9.
11.
•• Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136–45. This open-label PrEP demonstration project in Brazil reported that 450 individuals initiated PrEP in a real-world delivery setting through public healthcare clinics and found very high retention rates (83%) on PrEP by week 48. In addition, 74% of participants had high levels of PrEP drug concentrations indicating approximately four doses per week at the week 48 visit.
12.
Gill K, Dietrich J, Gray G, Pidwell T, Kayamba E, Bennie, T, Myer L, Johnson L, Spiegel H, Slack C, Elharrar V, Strode A, Rooney J, Bekker LG. Pluspills: an open label, safety and feasibility study of oral pre-exposure prophylaxis (PrEP) in 15–19 year old adolescents in two sites in South Africa. Abstract #TUAC0207LB. Oral presentation at the 9th International AIDS Society Conference (IAS) on HIV Science; July 23–26, 2017; Paris, France.
13.
Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21(5):1361–75.CrossRef
14.
• Allison BA, Widman L, Stewart JL, Evans R, Perry M. Adherence to pre-exposure prophylaxis in adolescents and young adults: a systematic review and meta-analysis. J Adolesc Health. 2021;S1054–139X(21)00169–5. This meta-analysis provides data on PrEP adherence across PrEP trials in a number of settings and populations. The findings reveal that adolescent girls and young women had lower adherence than other young key populations (about 46% of adolescent girls and young women adhered to PrEP across PrEP studies).
15.
•• Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670. This manuscript presents findings from the HPTN 082 trial conducted with adolescent girls and young women in South Africa and Zimbabwe. The study did not find that drug-level feedback counseling improved PrEP adherence in this population, but PrEP continuation and HIV incidence were low overall.
16.
Essien T, Mhlanga N, Hinson K, Mzizi P, Johnson A, Chasakara C, et al. Engaging adolescent girls and young women in HPTN 082: lessons learned from an oral PrEP study. Poster presentation at the 10th International AIDS Society (IAS) Conference on HIV Science; July 21–24, 2019; Mexico City, Mexico.
17.
Cabral A, M Baeten J, Ngure K, Velloza J, Odoyo J, E Haberer J, et al. Intimate partner violence and self-reported pre-exposure prophylaxis interruptions among HIV-negative partners in HIV serodiscordant couples in Kenya and Uganda. J Acquir Immune Defic Syndr. 2018;77(2):154–9.
18.
Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463. This manuscript provides descriptive data on experiences of PrEP-related stigma, disclosure, and PrEP use among adolescent girls and young women in South Africa and Zimbabwe. Stigma was a barrier to PrEP disclosure shortly after PrEP initiation but disclosure skills could also be used to combat stigma over time.
19.
van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PloS One. 2014;9(2):e89118.
20.
Velloza J, Hosek S, Donnell D, Anderson PL, Chirenje M, Mgodi N, et al. Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. J Int AIDS Soc. 2021;24 Suppl 2:e25731.
21.
Pilgrim N, Jani N, Mathur S, Kahabuka C, Saria V, Makyao N, et al. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: the role of provider biases and quality of care. PloS One. 2018;13(4):e0196280.
22.
•• Dunbar MS, Kripke K, Haberer J, Castor D, Dalal S, Mukoma W, et al. Understanding and measuring uptake and coverage of oral pre-exposure prophylaxis delivery among adolescent girls and young women in sub-Saharan Africa. Sex Health. 2018;15(6):513–21. This manuscript describes an intervention-centric cascade for defining metrics around PrEP uptake and coverage for adolescent girls and young women (AGYW). It also emphasizes the need to reframe definitions of “low uptake” to focus on delivering oral PrEP to AGYW during periods of HIV risk when they most need PrEP.
23.
Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11(1):10–7.CrossRef
24.
Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22 Suppl 4:e25298.
25.
Haberer JE, Mugo N, Baeten JM, Pyra M, Bukusi E, Bekker LG. PrEP as a lifestyle and investment for adolescent girls and young women in Sub-Saharan Africa. J Int Assoc Provid AIDS Care. 2019;18:2325958219831011.CrossRef
26.
• Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73. This manuscript found that self-reported PrEP adherence metrics are of limited usefulness alone but their utility can be improved when combined with biomarker measures of PrEP adherence.
27.
Musinguzi N, Muganzi CD, Boum Y, Ronald A, Marzinke MA, Hendrix CW, et al. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS. 2016;30(7):1121–9.CrossRef
28.
Bekker L-G, Rebe K, Venter F, Maartens G, Moorhouse M, Conradie F, et al. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. South Afr J Hiv Med. 2016;17(1).
29.
•• Ongolly FK, Dolla A, Ngure K, Irungu EM, Odoyo J, Wamoni E, et al. “I just decided to stop:” understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya. J Acquir Immune Defic Syndr. 2021;87(1):e150–8. This manuscript describes experiences of PrEP discontinuation, including reasons for intentional discontinuation such as reduced HIV risk, in the context of a large PrEP roll-out program in Kenya.
30.
•• Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. PLoS Med. 2019;16(9):e1002885. This manuscript presents findings from a real-world PrEP implementation program, integrated with family planning service delivery, in Kenya and found that integrated servcies were feasible and acceptable for young women.
31.
• Gilbert HN, Wyatt MA, Pisarski EE, Muwonge TR, Heffron R, Katabira ET, et al. PrEP discontinuation and prevention-effective adherence: experiences of PrEP users in Ugandan HIV serodiscordant couples. JAIDS. 2019 Nov 1;82(3):265. This manuscript describes qualitative experiences of PrEP continuation and discontinuation among HIV sero-discordant couples. The authors found that participants saw discontinuation as a loss of HIV protection even when partners living with HIV were virally suppressed, citing challenges for real-world counseling about effective PrEP use.
32.
Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277–85.CrossRef
33.
Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. J Int AIDS Soc. 2017;20(1).
34.
• Scorgie F, Khoza N, Delany-Moretlwe S, Velloza J, Mangxilana N, Atujuna M, et al. Narrative sexual histories and perceptions of HIV risk among young women taking PrEP in southern Africa: findings from a novel participatory method. Soc Sci Med. 2020;270:113600. This manuscript describes findings from a novel qualitative approach to capture information on HIV risk perceptions and desires for PrEP related to sexual partnerships. Adolescent girls and young women were most concerned about HIV in relationships where they felt a lack of trust and agency.
35.
• Muwonge TR, Ngure K, Katabira E, Mugo N, Kimemia G, Burns BFO, et al. Short message service (SMS) surveys assessing pre-exposure prophylaxis (PrEP) adherence and sexual behavior are highly acceptable among HIV-uninfected members of serodiscordant couples in East Africa: a mixed methods study. AIDS Behav. 2019;23(5):1267–1276. The authors assessed the acceptability and feasibility of using SMS surveys to collect sexual behavior data and found that most participants reported the SMS messages were easy to use and preferable to clinic questionnaires.
36.
•• Haberer JE, Bukusi EA, Mugo NR, Pyra M, Kiptinness C, Oware K, et al. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. Lancet HIV. 2021;8(3):e130–7. This manuscript presents findings from the MPYA randomized trial of an SMS-based PrEP adherence support intervention. They found that SMS reminders were ineffective in promoting PrEP adherence among young Kenyan women.
37.
Georgette N, Siedner MJ, Zanoni B, Sibaya T, Petty CR, Carpenter S, et al. The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal. South Africa AIDS Behav. 2016;20(11):2629–38.CrossRef
38.
•• Rousseau-Jemwa E, Bekker L-G, Bukusi E, Delaney-Moretlwe S, Omollo V, Travill D, et al. Early persistence of HIV pre-exposure prophylaxis (PrEP) in African adolescent girls and young women (AGYW) from Kenya and South Africa. AIDS Res Hum Retroviruses. 2018;34:68–68. This manuscript reviews findings from PrEP demonstration projects for adolescent girls and young women and found that PrEP is feasible for implementation in sexual and reproductive health service delivery models.
39.
Travill D, Bekker L-G, Delaney-Moretlwe S, Bukusi E, Imrie J, Rousseau-Jemwa E, et al. Sexual behavior and PrEP uptake among young African women in a demonstration project about PrEP delivery. Abstract #WEPEC219. Oral Presentation at the 9th International AIDS Society Conference (IAS); July 23–27, 2018; Amsterdam, the Netherlands.
40.
Celum C, Mgodi N, Bekker LG, Hosek S, Donnell D, Anderson PL, Dye BJ, Pathak S, Agyei Y, Fogel JM, Marzinke MA, Makgamathe K, Kassim S, Mukaka S, Noble H, Adeyeye A, Delany-Moretlwe S, on behalf of the HPTN 082 study team. PrEP adherence and effect of drug level feedback among young African women in HPTN 082. Abstract #TUAC0301. Oral presentation at the International AIDS Society Conference (IAS); July 21–24, 2019; Mexico City, Mexico.
41.
Chen Y, Ronen K, Matemo D, Unger JA, Kinuthia J, John-Stewart G, Levin C. An interactive text messaging intervention to improve adherence to Option B+ prevention of mother-to-child HIV transmission in Kenya: cost analysis. JMIR mHealth uHealth. 2020;8(10):e18351.
42.
Babigumira JB, Barnhart S, Mendelsohn JM, Murenje V, Tshimanga M, Mauhy C, Holeman I, Xaba S, Holec MM, Makunike-Chikwinya B, Feldacker C. PloS One. 2020;15(9):e0239915.
43.
van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3Suppl 2).
44.
•• Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020;23(11):e25636. This manuscript presents findings from the 3P study, which provided incentives to promote PrEP adherence among adolescent girls and young women in South Africa. The study did not find a significant effect of the interventions but PrEP adherence and persistence was high in the cohort.
45.
Colombini M, Mayhew SH, Mutemwa R, Kivunaga J, Ndwiga C, Team TI. Perceptions and experiences of integrated service delivery among women living with HIV attending reproductive health services in Kenya: a mixed methods study. AIDS Behav. 2016;20(9):2130–40.CrossRef
46.
Delaney-Moretlwe S, Chersich M, Harvey S, Stangl A, Baron D, Columbini M, et al. Empowerment clubs did not increase PrEP continuation among adolescent girls and young women in South Africa and Tanzania — results from the EMPOWER randomised trial. Abstract # FRAE0108LB. Oral presentation at the 9th International AIDS Society Conference (IAS); July 23–27, 2018; Amsterdam, the Netherlands.
47.
• Baron D, Scorgie F, Ramskin L, Khoza N, Schutzman J, Stangl A, et al. “You talk about problems until you feel free”: South African adolescent girls’ and young women’s narratives on the value of HIV prevention peer support clubs. BMC Public Health. 2020;20(1):1016. This manuscript presents qualitative data from the EMPOWER study, providing insights into the benefits of support groups around gender-based violence and PrEP use.
48.
• Masyuko S, Mukui I, Njathi O, Kimani M, Oluoch P, Wamicwe J, et al. Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study. Sex Health. 2018;15(6):578–86. This manuscript describes the Kenyan experience of rolling out PrEP for high risk populations, including adolescent girls and young women, and could serve as a model for other settings.
49.
Coombs A, Gold E. Generating Demand for PrEP: a desk review. Arlington, VA, USA; 2019. (Strengthening High Impact Interventions for an AIDS-Free Generation Project).
50.
• Morton JF, Myers L, Gill K, Bekker L-G, Stein G, Thomas KK, et al. Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. Gates Open Res. 2020;4:29. This manuscript describes the use of a behavior-centered design (BCD) approach to develop a PrEP social marketing campaign for adolescent girls and young women in South Africa. Participants discussed desires for a positively framed, empowering PrEP demand creation video.
51.
Mark D, Hrapcak S, Ameyan W, Lovich R, Ronan A, Schmitz K, et al. Peer support for adolescents and young people living with HIV in sub-Saharan Africa: emerging insights and a methodological agenda. Curr HIV/AIDS Rep. 2019;16(6):467–74.CrossRef
52.
Agunda P, Mutisya E, Musau A, Odera C, Maikweki L, Wango B, et al. Increasing Uptake of Oral Pre-Exposure Prophylaxis among Adolescent Girls and Young Women through Youth Peer Providers in Migori County, Kenya. Abstract #44. Oral presentation at the International Workshop on HIV and Adolescence; 2019; Nairobi, Kenya.
53.
• Wood S, Gross R, Shea JA, Bauermeister JA, Franklin J, Petsis D, et al. Barriers and facilitators of PrEP adherence for young men and transgender women of color. AIDS Behav. 2019;23(10):2719–29. This manuscript describes findings from a qualitative study on barriers and facilitators for PrEP use among young men who have sex with men and transgender women. Barriers included stigma, health systems inaccessibility, side effects, competing stressors, and low HIV risk perception.
54.
Pintye J, Beima-Sofie KM, Makabong’O PA, Njoroge A, Trinidad SB, Heffron RA, et al. HIV-uninfected Kenyan adolescent and young women share perspectives on using pre-exposure prophylaxis during pregnancy. AIDS Patient Care STDs. 2018;32(12):538–44.
55.
Wechsberg W, Ahmed K, Ndirangu J, Browne FA, Bonner C, Speizer I, et al. Can we end HIV among adolescent girls and young women in South Africa? Key challenges with PrEP. Abstract #4042.0. Oral presentation at the American Public Health Association Annual Meeting; November 2-6, 2019; Philadephia, PA, USA.
56.
WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 12: Adolescents and young adults. Geneva, Switzerland: World Health Organization; 2018. Report No.: License: CC BY-NC-SA 3.0 IGO.
57.
•• Hill BJ, Anderson B, Lock L. COVID-19 Pandemic, Pre-exposure Prophylaxis (PrEP) care, and HIV/STI testing among patients receiving care in three HIV epidemic priority states. AIDS Behav. 2021;25(5):1361–5. This manuscript provides data on the use of a telehealth/telePrEP approach to promote PrEP prescribing during the COVID pandemic.
58.
Alwang’a H. DREAMS goes digital: using virtual platforms to maintain PrEP access among adolescent girls and young women in Kenya. Presentation at the 23rd International AIDS Conference; July 6–10, 2020; Virtual.
59.
• Maseko B, Hill LM, Phanga T, Bhushan N, Vansia D, Kamtsendero L, et al. Perceptions of and interest in HIV pre-exposure prophylaxis use among adolescent girls and young women in Lilongwe, Malawi. PloS One. 2020;15(1):e0226062. This manuscript describes facilitators and barriers to PrEP delivery in Malawi. Adolescent girls and young women reported preferences that PrEP is delivered in youth-friendly sections of health centers with youth-friendly counseling messages.
60.
Pintye J, Kinuthia J, Roberts DA, Wagner AD, Mugwanya K, Abuna F, et al. Brief report: integration of PrEP services into routine antenatal and postnatal care: experiences from an implementation program in Western Kenya. J Acquir Immune Defic Syndr. 2018;79(5):590–5.CrossRef
61.
• Ortblad KF, Mogere P, Roche S, Kamolloh K, Odoyo J, Irungu E, et al. Design of a care pathway for pharmacy-based PrEP delivery in Kenya: results from a collaborative stakeholder consultation. BMC Health Serv Res. 2020;20(1):1034. The authors describe the development of a pharmacy-based PrEP delivery model, where stakeholders participated in workshops to describe possible challenges with pharmacy-based PrEP delivery and potential implementation approaches.
62.
Ortblad KF, Mogere P, Bukusi E, Ngure K, Baeten JM. Pharmacy delivery to expand the reach of PrEP in Africa. J Int AIDS Soc. 2020;23(9):e25619.
63.
• Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019;6(11):e788–99.
Metadaten
Titel
Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research
verfasst von
Elizabeth Irungu
Nomhle Khoza
Jennifer Velloza
Publikationsdatum
31.10.2021
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 6/2021
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00576-9

Weitere Artikel der Ausgabe 6/2021

Current HIV/AIDS Reports 6/2021 Zur Ausgabe

Co-infections and Comorbidity (D Bhattacharya, Section Editor)

HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Novel Platforms for Biomedical HIV Prevention Delivery to Key Populations — Community Mobile Clinics, Peer-Supported, Pharmacy-Led PrEP Delivery, and the Use of Telemedicine

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?

Central Nervous System and Cognition (SS Spudich, Section Editor)

Validity of Digital Assessments in Screening for HIV-Related Cognitive Impairment: a Review

Central Nervous System and Cognition (S Spudich, Section Editor)

Global Systematic Review of Common Mental Health Disorders in Adults Living with HIV

Correction

Correction to: Interventions Addressing Depression and HIV-Related Outcomes in People with HIV

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise